Biomarin Pharmaceutical Inc logo

BMRN - Biomarin Pharmaceutical Inc Share Price

$82.97 1.6  2.0%

Last Trade - 15/01/21

Large Cap
Market Cap £11.09bn
Enterprise Value £11.05bn
Revenue £1.37bn
Position in Universe 664th / 6543
Unlock BMRN Revenue
Relative Strength (%)
1m -8.86%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -37.1%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
749.3 889.9 1,117 1,314 1,491 1,704 1,851 1,920 +17.9%
Balance Sheet
FINANCIAL BRIEF: : For the nine months ended 30 September 2020,BioMarin Pharmaceutical Inc. revenues increased 13% to$1.41B. Net income totaled $837M vs. loss of $38.9M.Revenues reflect Palynziq1 segment increase from $55.3M to$121.4M, Aldurazyme1 segment increase of 74% to $128.9M,United States segment increase of 30% to $729.7M, Rest ofworld segment increase of 5% to $161.4M.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for BMRN
Graphical History


BMRN Revenue Unlock BMRN Revenue

Net Income

BMRN Net Income Unlock BMRN Revenue

Normalised EPS

BMRN Normalised EPS Unlock BMRN Revenue

PE Ratio Range

BMRN PE Ratio Range Unlock BMRN Revenue

Dividend Yield Range

BMRN Dividend Yield Range Unlock BMRN Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
BMRN EPS Forecasts Unlock BMRN Revenue
Profile Summary

BioMarin Pharmaceutical Inc. is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company's therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A). The Company is conducting clinical trials on various product candidates for the treatment of various diseases. Its clinical product candidates include Brineura, pegvaliase, vosoritide, BMN 270 and BMN 250.

Last Annual December 31st, 2019
Last Interim September 30th, 2020
Incorporated October 25, 1996
Public Since July 21, 2009
No. of Shareholders: 44
No. of Employees: 3,001
Sector Healthcare
Industry Pharmaceuticals
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 181,529,667
Free Float (0.0%)
Eligible for
BMRN Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for BMRN
Upcoming Events for BMRN
Wednesday 24th February, 2021 Estimate
Q4 2020 Biomarin Pharmaceutical Inc Earnings Release
Tuesday 27th April, 2021 Estimate
Q1 2021 Biomarin Pharmaceutical Inc Earnings Release
Frequently Asked Questions for Biomarin Pharmaceutical Inc
What is the Biomarin Pharmaceutical Inc share price?

As of 15/01/21, shares in Biomarin Pharmaceutical Inc are trading at $82.97, giving the company a market capitalisation of £11.09bn. This share price information is delayed by 15 minutes.

How has the Biomarin Pharmaceutical Inc share price performed this year?

Shares in Biomarin Pharmaceutical Inc are currently trading at $82.97 and the price has moved by -6.91% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Biomarin Pharmaceutical Inc price has moved by -18.34% over the past year.

What are the analyst and broker recommendations for Biomarin Pharmaceutical Inc?

Of the analysts with advisory recommendations for Biomarin Pharmaceutical Inc, there are there are currently 6 "buy" , 9 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Biomarin Pharmaceutical Inc is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Biomarin Pharmaceutical Inc next release its financial results?

Biomarin Pharmaceutical Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-09-30
What is the Biomarin Pharmaceutical Inc dividend yield?

Biomarin Pharmaceutical Inc does not currently pay a dividend.

Does Biomarin Pharmaceutical Inc pay a dividend?

Biomarin Pharmaceutical Inc does not currently pay a dividend.

When does Biomarin Pharmaceutical Inc next pay dividends?

Biomarin Pharmaceutical Inc does not currently pay a dividend.

How do I buy Biomarin Pharmaceutical Inc shares?

To buy shares in Biomarin Pharmaceutical Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Biomarin Pharmaceutical Inc?

Shares in Biomarin Pharmaceutical Inc are currently trading at $82.97, giving the company a market capitalisation of £11.09bn.

Where are Biomarin Pharmaceutical Inc shares listed? Where are Biomarin Pharmaceutical Inc shares listed?

Here are the trading details for Biomarin Pharmaceutical Inc:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: BMRN
What kind of share is Biomarin Pharmaceutical Inc?

Based on an overall assessment of its quality, value and momentum, Biomarin Pharmaceutical Inc is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Biomarin Pharmaceutical Inc share price forecast 2021?

Shares in Biomarin Pharmaceutical Inc are currently priced at $82.97. At that level they are trading at 33.66% discount to the analyst consensus target price of 0.00.

Analysts covering Biomarin Pharmaceutical Inc currently have a consensus Earnings Per Share (EPS) forecast of 4.234 for the next financial year.

How can I tell whether the Biomarin Pharmaceutical Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Biomarin Pharmaceutical Inc. Over the past six months, the relative strength of its shares against the market has been -44.56%. At the current price of $82.97, shares in Biomarin Pharmaceutical Inc are trading at -10.67% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Biomarin Pharmaceutical Inc PE Ratio?

The Biomarin Pharmaceutical Inc PE ratio based on its reported earnings over the past 12 months is 20.56. The shares are currently trading at $82.97.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Biomarin Pharmaceutical Inc?

Biomarin Pharmaceutical Inc's management team is headed by:

Elaine Heron - IND
G. Eric Davis - EVP
Jean-Jacques Bienaime - CHM
Michael Grey - IND
Jeff Ajer - EVP
Richard Meier - LED
Henry Fuchs - CEX
Brian Mueller - CFO
Willard Dere - IND
Elizabeth Anderson - IND
Lon Cardon - CSO
C. Greg Guyer - EVP
Andrea Acosta - CAO
Who are the major shareholders of Biomarin Pharmaceutical Inc?

Here are the top five shareholders of Biomarin Pharmaceutical Inc based on the size of their shareholding:

Capital Research Global Investors Investment Advisor
Percentage owned: 12.15% (22.1m shares)
PRIMECAP Management Company Investment Advisor
Percentage owned: 10% (18.1m shares)
The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 9% (16.3m shares)
American Funds AMCAP Fund Mutual Fund
Percentage owned: 5.72% (10.4m shares)
BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 5.43% (9.86m shares)
Similar to BMRN
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.